Abstract
Biogenic silver nanoparticles (b-AgNPs) were produced extracellularly using a cell lysate of genetically modified Escherichia coli and subdivided into three groups. Each group received a different treatment to determine which one best removed residual cell lysate material. The first group was treated twice using only water (water ×2), the second using 8M urea once (8M urea ×1), and the third using 8M urea twice (8M urea ×2). Subsequently, each group was assessed for its ability to inhibit the growth of six bacterial and two fungal pathogens. Testing was accomplished using the minimum inhibitory concentration (MIC) method. Commercially produced c-AgNPs were included for comparison. In all cases, the b-AgNPs (8M urea ×2) demonstrated the greatest inhibition of microbe growth. Conversely, the commercial AgNPs failed to show any growth inhibition at 10 µg/mL the highest concentration tested. The greater antibacterial activity of the b-AgNPs (8M urea ×2) over both b-AgNPs (8M urea ×1) and b-AgNPs (water ×2) is thought to be due to a larger degree of biofunctionalization (coating) occurring during the two sequential 8M urea treatments.
Funder
the Pat Capps Covey College of Allied Health Professions, University of South Alabama
Department of Defense/Army Research Office
Subject
Polymers and Plastics,General Environmental Science
Reference30 articles.
1. Silver nanoparticles: Synthesis, characterisation and biomedical applications;Almatroudi;Open Life Sci.,2020
2. Lee, S.H., and Jun, B.-H. Silver Nanoparticles: Synthesis and Application for Nanomedicine. Int. J. Mol. Sci., 2019. 20.
3. Toxicological studies on silver nanoparticles: Challenges and opportunities in assessment, monitoring and imaging;Stensberg;Nanomedicine,2011
4. Bouafia, A., Laouini, S.E., Ahmed, A.S.A., Soldatov, A.V., Algarni, H., Chong, K.F., and Ali, G.A.M. The Recent Progress on Silver Nanoparticles: Synthesis and Electronic Applications. Nanomaterials, 2021. 11.
5. Silver Nanoparticles Market Size, Share—Industry Forecast, 2030. 2022.